PLAGL2-EGFR-HIF-1/2α信号环路促进肝细胞癌进展并介导厄洛替尼不敏感
该研究探讨PLAGL2在肝细胞癌(HCC)中的作用,发现PLAGL2在HCC中表达上调并与总生存时间相关,可促进HCC细胞增殖、迁移和侵袭。机制上PLAGL2作为EGFR的转录调控因子,通过EGFR-AKT通路发挥作用,并与缺氧诱导的HIF1/2A形成PLAGL2-EGFR-HIF1/2A信号环路促进HCC进展;PLAGL2表达还降低肝癌细胞对厄洛替尼的应答,敲低PLAGL2可增强厄洛替尼敏感性。
要点
- PLAGL2在HCC中表达上调,与总生存时间相关,并促进HCC细胞增殖、迁移和侵袭。
- PLAGL2作为EGFR的转录调控因子,经EGFR-AKT通路促进HCC进展。
- PLAGL2降低肝癌细胞对厄洛替尼的应答,敲低PLAGL2可增强厄洛替尼敏感性。
核心结论
- PLAGL2在HCC细胞增殖、转移及厄洛替尼不敏感中发挥关键作用,提示其可作为HCC的潜在治疗靶点。
研究设计与样本
- 研究比较HCC与癌旁非肿瘤组织中PLAGL2的表达,并分析其与总生存时间的相关性。
- 通过体外和体内实验评估PLAGL2对HCC细胞增殖、迁移和侵袭的影响。
- 机制研究探讨PLAGL2对EGFR的转录调控及EGFR-AKT通路、缺氧诱导的HIF1/2A表达。
主要发现
- PLAGL2在HCC中较癌旁非肿瘤组织表达上调,并与总生存时间相关。
- PLAGL2在体外和体内均促进HCC细胞增殖、迁移和侵袭。
- PLAGL2表达与EGFR表达呈正相关。
- 缺氧可显著诱导PLAGL2高表达,后者通过EGFR促进HIF1/2A表达,形成PLAGL2-EGFR-HIF1/2A信号环路。
- PLAGL2表达降低肝癌细胞对厄洛替尼的应答,敲低PLAGL2可增强对厄洛替尼的应答。
临床怎么用
- PLAGL2表达状态可能作为HCC预后相关分子标志物及潜在治疗靶点。
- 对厄洛替尼应答不佳的HCC,敲低PLAGL2可能增强抗EGFR治疗敏感性,但尚需临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide, hence a major public health threat. Pleomorphic adenoma gene like-2 (PLAGL2) has been reported to play a role in tumorigenesis. However, its precise function in HCC remains poorly understood. APPROACH AND RESULTS: In this study, we demonstrated that PLAGL2 was up-regulated in HCC compared with that of adjacent nontumorous tissues and also correlated with overall survival times. We further showed that PLAGL2 promoted HCC cell proliferation, migration, and invasion both in vitro and in vivo. PLAGL2 expression was positively correlated with epidermal growth factor receptor (EGFR) expression. Mechanistically, this study demonstrated that PLAGL2 functions as a transcriptional regulator of EGFR and promotes HCC cell proliferation, migration, and invasion through the EGFR-AKT pathway. Moreover, hypoxia was found to significantly induce high expression of PLAGL2, which promoted hypoxia inducible factor 1/2 alpha subunit (HIF1/2A) expression through EGFR. Therefore, this study demonstrated that a PLAGL2-EGFR-HIF1/2A signaling loop promotes HCC progression. More importantly, PLAGL2 expression reduced hepatoma cells' response to the anti-EGFR drug erlotinib. PLAGL2 knockdown enhanced the response to erlotinib. CONCLUSIONS: This study reveals the pivotal role of PLAGL2 in HCC cell proliferation, metastasis, and erlotinib insensitivity. This suggests that PLAGL2 can be a potential therapeutic target of HCC.
引用
- Hu W, Zheng S, Guo H, et al. PLAGL2-EGFR-HIF-1/2α Signaling Loop Promotes HCC Progression and Erlotinib Insensitivity. Hepatology. 2021. PMID: 32335942. doi:10.1002/hep.31293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。